Cero Therapeutics grants CFO options on 1,162,099 shares at $0.055
Cero Therapeutics Holdings, Inc. granted its Chief Financial Officer, Andrew Kucharchuk, a stock option on January 7, 2026.
Rhea-AI Filing Summary
Cero Therapeutics Holdings, Inc. granted its Chief Financial Officer, Andrew Kucharchuk, a stock option on January 7, 2026. The option gives the right to buy 1,162,099 shares of common stock at an exercise price of $0.055 per share. The option is listed as exercisable beginning January 7, 2026 and expires on January 6, 2036. Following this grant, Kucharchuk is reported as directly beneficially owning 1,162,099 derivative securities of this type.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 1,162,099 | $0.00 | $0.00 |
FAQ
What insider transaction did CERO report for its CFO?
Cero Therapeutics Holdings, Inc. reported that its Chief Financial Officer, Andrew Kucharchuk, received a grant of stock options on January 7, 2026.
What is the exercise price of the CERO stock options granted to the CFO?
The options have a conversion or exercise price of $0.055 per share for the underlying common stock.
When do the newly granted CERO stock options expire?
The options are shown as exercisable starting on January 7, 2026 and have an expiration date of January 6, 2036.
Is the CERO CFO’s ownership reported as direct or indirect?
The filing reports direct beneficial ownership of 1,162,099 derivative securities following the transaction.
What SEC form was used to disclose the CERO CFO’s stock option grant?
The transaction was disclosed on a Form 4, which reports changes in beneficial ownership by company insiders.
AI-generated analysis. How Rhea-AI works. Not financial advice.